within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AA02_DocusateSodium;

model DocusateSodium
  extends Pharmacolibrary.Drugs.ATC.A.A06AA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A06AA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Docusate sodium is an anionic surfactant stool softener used for the treatment of constipation. It acts by increasing the amount of water the stool absorbs in the gut, making the stool softer and easier to pass. It is an over-the-counter medication widely used and approved for treating occasional constipation.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical healthy adult population. No direct published human plasma PK data is available; parameters estimated from limited human and animal data and pharmacological knowledge.</p><h4>References</h4><ol><li><p>Persaud, N, et al., &amp; Oliver, W (1985). The relative bioavailability of paracetamol and codeine after oral administration of a combination of buclizine, paracetamol and codeine, with or without docusate, and of paracetamol alone in healthy volunteers. <i>Current medical research and opinion</i> 9(9) 626–633. DOI:<a href=&quot;https://doi.org/10.1185/03007998509109644&quot;>10.1185/03007998509109644</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2414066/&quot;>https://pubmed.ncbi.nlm.nih.gov/2414066</a></p></li><li><p>Noh, G, et al., &amp; Lee, S (2023). Assessment of hydrophobic-ion paired insulin incorporated SMEDDS for the treatment of diabetes mellitus. <i>International journal of biological macromolecules</i> 225 911–922. DOI:<a href=&quot;https://doi.org/10.1016/j.ijbiomac.2022.11.155&quot;>10.1016/j.ijbiomac.2022.11.155</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36403777/&quot;>https://pubmed.ncbi.nlm.nih.gov/36403777</a></p></li><li><p>Sutar, Y, et al., &amp; Date, AA (2025). Rilpivirine Ionic Liquid Nanoemulsion Augments the Oral Bioavailability of Rilpivirine and Its Delivery to the HIV Sanctuary Sites. <i>ACS applied materials &amp; interfaces</i> 17(22) 31954–31970. DOI:<a href=&quot;https://doi.org/10.1021/acsami.5c05456&quot;>10.1021/acsami.5c05456</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40392184/&quot;>https://pubmed.ncbi.nlm.nih.gov/40392184</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end DocusateSodium;
